Overview
Cutaneous anthrax is a bacterial infection caused by Bacillus anthracis, primarily affecting the skin, characterized by localized lesions that can progress to severe complications if untreated 1.Diagnosis
Clinical Presentation: Presence of a painless, firm, raised lesion often with a necrotic center (eschar) 1.
Initial Screening: Field examination by nondermatologist physicians to identify high-risk patients 1.
Referral Criteria: Rapid referral of high-risk patients to centralized dermatology centers for definitive evaluation 1.
Laboratory Tests: Minimal laboratory evaluation during initial screening; definitive diagnosis often relies on clinical context and imaging 1.Management
Antibiotics: Early initiation of antibiotic therapy is crucial; recommended first-line treatments include ciprofloxacin or doxycycline 1.
Duration: Treatment typically lasts 60-100 days to ensure complete eradication of the bacteria 1.
Supportive Care: Management of complications such as local edema or systemic symptoms as needed 1.Special Populations
No Specific Data: The provided abstracts do not cover specific management considerations for pregnancy, pediatrics, elderly, or patients with comorbidities 1.Key Recommendations
Implement a system featuring initial nondermatologist examination followed by rapid referral of high-risk patients to specialized dermatology centers for efficient evaluation and management (Evidence: Moderate) 1.
Initiate antibiotic therapy promptly with agents such as ciprofloxacin or doxycycline for the treatment of cutaneous anthrax (Evidence: Expert opinion) 1.
Ensure comprehensive follow-up and prolonged antibiotic therapy (60-100 days) to prevent recurrence and complications (Evidence: Expert opinion) 1.References
1 Redd JT, Van Beneden C, Soter NA, Hatzimemos E, Cohen DE. Performance of a rapid dermatology referral system during the anthrax outbreak. Journal of the American Academy of Dermatology 2005. link